Clinical Trials for Fallopian Tube Endometrioid Adenocarcinoma | Kisho | Kisho

Back to Fallopian Tube Endometrioid Adenocarcinoma

Fallopian Tube Endometrioid Adenocarcinoma — Clinical Trials

MONDO:000366617 active·6 recruitingLast updated: Mar 15, 2026, 6:27 PM

Trial Landscape

Fallopian Tube Endometrioid Adenocarcinoma has a growing clinical research program, driven by drug treatment and procedure.

6

Recruiting

17

Active Trials

By Approach

Drug Treatment14

Procedure14

Biological Therapy12

8 additional trials involve behavioral, dietary, diagnostic, or observational approaches.

By Phase

Early Phase 1

1

Phase 1

4

Phase 2

11

Phase 3

5

Sponsor Types

NIH10Academic/Other7

Trial Locations

United States17 trials

Puerto Rico4 trials

Japan3 trials

South Korea3 trials

Canada3 trials

Trials often recruit across multiple countries, so totals exceed the trial count.

17 Trials

Phase 3Recruiting

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Sponsor:NRG Oncology

United StatesStarted: Mar 2025Est. completion: Dec 2034Updated: Jan 2026

Phase 2Recruiting

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Sponsor:Roswell Park Cancer Institute

United StatesStarted: Mar 2024Est. completion: Dec 2026Updated: Nov 2025

Phase 2Recruiting

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Sponsor:Mayo Clinic

United StatesStarted: Nov 2024Est. completion: Dec 2027Updated: Oct 2025

Phase 2Recruiting

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Sponsor:Roswell Park Cancer Institute

United StatesStarted: Apr 2023Est. completion: Apr 2027Updated: May 2025

Phase 1Recruiting

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Sponsor:Mayo Clinic

United StatesStarted: Sep 2023Est. completion: Jul 2027Updated: Jun 2025

Early Phase 1Recruiting

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

Sponsor:Ohio State University Comprehensive Cancer Center

United StatesStarted: Jun 2022Est. completion: Dec 2026Updated: Feb 2026

Phase 3Active, Not Recruiting

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Sep 2010Est. completion: Jul 2026Updated: Mar 2026

Phase 3Active, Not Recruiting

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Dec 2007Est. completion: Jan 2028Updated: Dec 2025

Phase 2Active, Not Recruiting

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Dec 2019Est. completion: Feb 2027Updated: Mar 2026

Phase 2Active, Not Recruiting

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jun 2017Est. completion: Mar 2026Updated: Mar 2026

Phase 2Active, Not Recruiting

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: May 2016Est. completion: Nov 2026Updated: Mar 2026

Phase 2Active, Not Recruiting

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: May 2016Est. completion: Dec 2026Updated: Mar 2026

Phase 2Active, Not Recruiting

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jun 2021Est. completion: Nov 2026Updated: Mar 2026

Phase 2Active, Not Recruiting

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Oct 2018Est. completion: Oct 2026Updated: Oct 2025

Phase 1Active, Not Recruiting

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: May 2020Est. completion: Jun 2026Updated: Mar 2026

Phase 1Active, Not Recruiting

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Sep 2022Est. completion: Feb 2026Updated: Dec 2025

Stay informed about clinical trials for Fallopian Tube Endometrioid Adenocarcinoma.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 15, 2026 at 6:27 PM